---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-23-000064"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:05:21.365314+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics reports Q3 2023 net loss of $39.4M; advances KER-050, deprioritizes KER-047

## Summary
- Net loss of $39.4M in Q3 2023 vs $23.5M in Q3 2022, driven by increased R&D spending.
- R&D expenses rose to $34.1M from $21.0M; G&A rose to $9.1M from $6.9M.
- Cash and equivalents of $287.9M provide runway into Q4 2025.
- KER-047 program deprioritized; Phase 2 trial in MDS/myelofibrosis being terminated early.
- KER-065 Phase 1 trial in healthy adults expected to start in Q1 2024.

## SEC filing metadata
- accession: 0001664710-23-000064
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000064/0001664710-23-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000064/kros-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-23-000064
- JSON: https://secwatch.observer/filing/0001664710-23-000064.json
- Plain text: https://secwatch.observer/filing/0001664710-23-000064.txt

## Key facts
- Earnings Releases
  Keros Therapeutics, Inc. reported for the quarter ended September 30, 2023 results: net income net loss of $39.4 million.
  - Period: for the quarter ended September 30, 2023
  - Net income: net loss of $39.4 million
  - Result: reported results
  source text: Keros reported a net loss of $39.4 million in the third quarter of 2023 as compared to a net loss of $23.5 million in the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000064/0001664710-23-000064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.